Register
|
Login
Member Services
About ASCPT
Strategic Plan
ASCPT History
ASCPT Past Presidents
ASCPT Statement on Diversity, Equity, and Inclusion
Low-to-Middle Income Country Accelerator Program
ASCPT Awards
Awards Recipients
ASCPT-FDA William Abrams Award Lecture
Leadership Blog
Committees and Task Forces
Anti-Harassment Policy and Procedure
ASCPT Bylaws
Member Tools
Get Involved
Join ASCPT
I am ASCPT
Online Learning
ASCPT Podcasts
Identity Groups
Networks and Communities
Quantitative Pharmacology
Biologics
Pharmacometrics & Pharmacokinetics
Physiologically Based Pharmacokinetic Modeling and Simulation
Systems Pharmacology
Translational Informatics
Translational & Precision Medicine
Biomarkers & Translational Tools
Infectious Diseases
Membrane Transporter
Mental Health & Addiction
Oncology
Pharmacogenomics
Precision Dosing
Rare Diseases
Specific Populations
Development, Regulatory, & Outcomes
Cell, Gene, Regenerative Medicine & Nucleic Acid
Drug Utilization & Outcomes
Early Development & Drug Safety
Global Health
Life Cycle Management Community
Regulatory Science
Early Career Community
Student & Trainee Community
Resources
ASCPT News
Career Center
Donate
Knowledge Center
What is Clinical Pharmacology?
What is Translational Science?
Tools and Resources
Communities of Practice
Online Learning
Meetings
Annual Meeting
Justification Toolkit
ASCPT 2025 Annual Meeting Platform
ASCPT 2024 Annual Meeting Platform
ASCPT 2023 Annual Meeting Platform
Network and Community Experience
Past & Future Annual Meetings
Journals
Call for Papers
Editors in Training
X
Member Services
About ASCPT
Strategic Plan
ASCPT History
ASCPT Past Presidents
ASCPT Statement on Diversity, Equity, and Inclusion
Low-to-Middle Income Country Accelerator Program
ASCPT Awards
Awards Recipients
ASCPT-FDA William Abrams Award Lecture
Leadership Blog
Committees and Task Forces
Anti-Harassment Policy and Procedure
ASCPT Bylaws
Member Tools
Get Involved
Join ASCPT
I am ASCPT
Online Learning
ASCPT Podcasts
Identity Groups
Networks and Communities
Quantitative Pharmacology
Biologics
Pharmacometrics & Pharmacokinetics
Physiologically Based Pharmacokinetic Modeling and Simulation
Systems Pharmacology
Translational Informatics
Translational & Precision Medicine
Biomarkers & Translational Tools
Infectious Diseases
Membrane Transporter
Mental Health & Addiction
Oncology
Pharmacogenomics
Precision Dosing
Rare Diseases
Specific Populations
Development, Regulatory, & Outcomes
Cell, Gene, Regenerative Medicine & Nucleic Acid
Drug Utilization & Outcomes
Early Development & Drug Safety
Global Health
Life Cycle Management Community
Regulatory Science
Early Career Community
Student & Trainee Community
Resources
ASCPT News
Career Center
Donate
Knowledge Center
What is Clinical Pharmacology?
What is Translational Science?
Tools and Resources
Communities of Practice
Online Learning
Meetings
Annual Meeting
Justification Toolkit
ASCPT 2025 Annual Meeting Platform
ASCPT 2024 Annual Meeting Platform
ASCPT 2023 Annual Meeting Platform
Network and Community Experience
Past & Future Annual Meetings
Journals
Call for Papers
Editors in Training
Oncology
Member Services
Networks and Communities
Translational & Precision Medicine
Oncology
Oncology (ONC) Community
Description & Goals
Community Goals
Provide forums for interactions of Community members to foster new relationships and provide interactive scientific discussion on current key issues in oncology.
Develop of best practices for Annual Meeting scientific programming proposals that leads to scientifically rich, well-developed collaborative proposals issues in oncology.
Utilize social media to post impactful publications or presentations, permit commentary, and promote discussion among members.
Standardize criteria to prioritize scientific proposals in collaboration with members of other Communities housed within the Translational & Precision Network.
Community Connection
Join the LinkedIn Group.
Past Webinars
The webinars below can be accessed in the
Members Only
Webinar Library:
Access Library
Minimum Anticipated Biological Effect Level (MABEL) for Selection of First-in-Human (FIH) Starting Dose of Immune-Activating Biotherapeutics Description (Part 2 of 2)
Recent Perspectives and Advances on the Development of Cell Therapies for Cancer
Clinical Trials in the Pediatric CKD Population: Challenges and Opportunities
A Semi-Mechanistic PK/PD Model to Project Undetectable Minimal Residual Disease Rates in Chronic Lymphocytic Leukemia Studies
Translational and Clinical Pharmacology Considerations in the Development of Immune Oncology Drugs (Encore Presentation)
Convergence of Therapeutic Approaches in Oncology and HIV to Target Immune Evasion: Integrating Clinical Pharmacology Lessons Learned
Using Preclinical Data in Phase I Oncology Trials: A Bayesian Decision Theoretic Approach
Translational and Clinical Pharmacology Considerations in the Development of Immune Oncology Drugs
IQ CPLG PWG: Strategies to Address Opportunities in Oncology Pediatric Drug
Clinical Pharmacological and Pharmacodynamic Perspectives on the Adverse Events of Cancer Immunotherapy
Leadership
Keroles Nakhla, BSc
Community Chair
Joseph Piscitelli, PharmD
Community Co-Vice Chair
Ping Xu, PhD
Community Co-Vice Chair
Jia Li, PhD
Community Past Chair
Steering Committee
Susan Colace, MD
Jaszianne Tolbert, MD
Nathan D. Seligson, PharmD
Dan Hertz, PharmD, PhD
Florence Hourcade-Potelleret, MD
Chirag Patel, PhD